Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Kent

Showing results (11-20 of 268) with videos related to

Pageof 27
Sort By:
Heart (British Cardiac Society)|May 1, 2012
Towards an epidemiology of the known unknowns in cryptogenic strokeIssa J Dahabreh, David M Kent
Trials|July 29, 2011
The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic strokeDavid M Kent, David E Thaler,
JAMA|November 26, 2009
Therapeutic innovations, diminishing returns, and control rate preservationDavid M Kent, Thomas A Trikalinos
BMJ (Clinical Research Ed.)|April 12, 2012
Personalised medicine: not just in our genesGeorgios D Kitsios, David M Kent
Annals of Internal Medicine|July 13, 2010
Aggregating and disaggregating patients in clinical trials and their subgroup analysesDavid M Kent, Peter K Lindenauer
Stroke|September 30, 2010
Is patent foramen ovale a modifiable risk factor for stroke recurrence?David M Kent, David E Thaler
Lancet (London, England)|January 9, 2003
Primary angioplasty or thrombolysis for acute myocardial infarction?David M Kent, Harry P Selker
The New England Journal of Medicine|March 22, 2013
Still no closure on the question of PFO closureSteven R Messé, David M Kent
JAMA|September 13, 2007
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratificationDavid M Kent, Rodney A Hayward
Current Treatment Options in Cardiovascular Medicine|November 16, 2014
Controversies in cardioembolic strokeBenjamin S Wessler, David M Kent
Pageof 27

Showing results (11-20 of 268) with videos related to

Sort By:
Pageof 27
Heart (British Cardiac Society)|May 1, 2012
Towards an epidemiology of the known unknowns in cryptogenic strokeIssa J Dahabreh, David M Kent
Trials|July 29, 2011
The Risk of Paradoxical Embolism (RoPE) Study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic strokeDavid M Kent, David E Thaler,
JAMA|November 26, 2009
Therapeutic innovations, diminishing returns, and control rate preservationDavid M Kent, Thomas A Trikalinos
BMJ (Clinical Research Ed.)|April 12, 2012
Personalised medicine: not just in our genesGeorgios D Kitsios, David M Kent
Annals of Internal Medicine|July 13, 2010
Aggregating and disaggregating patients in clinical trials and their subgroup analysesDavid M Kent, Peter K Lindenauer
Stroke|September 30, 2010
Is patent foramen ovale a modifiable risk factor for stroke recurrence?David M Kent, David E Thaler
Lancet (London, England)|January 9, 2003
Primary angioplasty or thrombolysis for acute myocardial infarction?David M Kent, Harry P Selker
The New England Journal of Medicine|March 22, 2013
Still no closure on the question of PFO closureSteven R Messé, David M Kent
JAMA|September 13, 2007
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratificationDavid M Kent, Rodney A Hayward
Current Treatment Options in Cardiovascular Medicine|November 16, 2014
Controversies in cardioembolic strokeBenjamin S Wessler, David M Kent
Pageof 27